bioRxivSystems BiologyPreprint
Longitudinal blood microsampling and proteome monitoring facilitate timely intervention in experimental type 1 diabetes
Anirudra ParajuliiD, Annika BendesiD, Fabian ByvaldiD, Virginia M. StoneiD, Emma E. RingqvistiD, Marta ButrymiD, Emmanouil Angelis, Sophie KipperiD, Stefan BaueriD, Niclas RoxhediD, Jochen M. SchwenkiD, Malin Flodström‐TullbergiD
Abstract
Symptoms of immune-mediated diseases (IMIDs) typically appear after irreversible tissue damage, making early interventions based on pre-symptomatic indicators crucial. Current efforts to identify molecular markers of early disease lack the resolution, convenience and cost efficiency required to prevent irreversible tissue damage. Analyzing frequently self-collected samples, such as dried blood spots (DBS), could enable the earlier detection of diseases, identify disease-predictive markers and facilitate tailored interventions. To test this, we regularly microsampled a mouse model infected with a type 1-diabetes (T1D)-associated virus. This longitudinal DBS sample collection was analyzed for 92 circulating proteins, revealing transient molecular changes in virus-infected animals that would have been missed with less frequent sampling. Machine learning predicted infection status after day 2 post-infection with >90% accuracy, enabling well-timed treatment of virus-infected animals and diabetes prevention. Our study demonstrates the utility of frequent blood microsampling to monitor disease during the pre-symptomatic phase, allowing for timely interventions. TeaserFrequent blood microsampling detects early biomarkers, enabling timely intervention in immune-mediated diseases
- organism: mouse
- assay: proteomics
- research focus: differential expression
- approach: machine learning (classical)
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Imaging mass cytometry reveals early β-cell dysfunction and changes in immune signatures during type 1 diabetes progression in human pancreata
Nathan Steenbuck, Nicolas Damond, … Bernd Bodenmiller·bioRxiv·Mar 5, 2025
- Assessing extracellular vesicle proteins as predictive biomarkers for developing type 1 diabetes
Panshak Dakup, Lisa M. Bramer, … Ernesto Satoshi Nakayasu·PROTEOMICSPeer-reviewed·May 20, 2026
- Loss of Exocytosis Protein DOC2B is an Early Event in Type 1 Diabetes Development
Diana Esparza, Eunjin Oh, … Debbie C. Thurmond·bioRxiv·Jan 6, 2026
- Synthetic Immunological Niche Reveals Early Immune Dysregulationand Stratifies Therapeutic Response in Type 1 Diabetes
Jyotirmoy Roy, Yifei Jiang, … Lonnie D. Shea·bioRxiv·Mar 10, 2026
- Dried Blood Spot Lipidomics in Diabetes
Jayden Lee Roberts, Monique Ryan, … Nathan G. Lawler·bioRxiv·May 28, 2025
- Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type1 diabetes therapeutic reversal in preclinical models
V. Pham, D. G. Ramirez, R. K. Benninger·bioRxiv·Mar 3, 2020